A Paradigm Use of Monoclonal Antibodies-conjugated Nanoparticles in Breast Cancer Treatment: Current Status and Potential Approaches.

Monoclonal antibodies (mAbs) are integral to cancer treatment over conventional non-specific therapy methods. This study provides a scoping review of the clinically approved mAbs, focusing on the current application of different nanocarrier technologies as drug delivery targets for mAb-conjugated nanoparticles as potential features for breast cancer treatment. An extensive literature search was conducted between the years 2000 and 2023 using various sources of databases. The first part covered mAb classification, types, and mechanisms of action, pharmacokinetics, and clinical applications in breast cancer. The second part covered polymeric, lipid, and inorganic-based nanoparticles, which are a variety of mAb-conjugated nanoparticles targeting breast cancer. A total of 20 relevant studies were enrolled indicating there are three different types of nanoparticular systems (polymeric NPs, inorganic NPs, and lipid-based NPs) that can be used for breast cancer treatment by being loaded with various active substances and conjugated with these antibodies. While mAbs have altered the way in cancer treatment due to targeting cancer cells specifically, the delivery of mAbs with nanoparticulate systems is important in the treatment of breast cancer, as nanoparticles are still being investigated as distinctive and promising drug delivery methods that can be employed for effective treatment of breast cancer.